Cleveland, OH Clinical Trials Report — June 2026

For individuals in Cleveland, OH, considering participation in clinical research, June 2026 presents a critical window of opportunity, with a significant number of trials nearing their enrollment deadlines. Across Cleveland, a total of 1,231 clinical trials are currently recruiting participants at 337 research facilities, offering diverse avenues to contribute to medical advancements.

Act Quickly: Trials Nearing Completion

Time is of the essence for those interested in specific research areas, as 86 clinical trials in Cleveland are slated to conclude enrollment within the next 90 days. This urgency is particularly relevant for healthy volunteers, with 5 of these rapidly closing studies still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical understanding before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke (3 trials)
• Advanced solid tumor (3 trials)
• Postoperative complications (2 trials)
• Metastatic cancer (2 trials)
• Ovarian cancer (2 trials)
• Tricuspid regurgitation (2 trials)
• Endometrial cancer (2 trials)
• Breast cancer (2 trials)
• Hepatic encephalopathy (2 trials)
• Epilepsy (2 trials)

New Research Horizons in Cleveland

This month, Cleveland saw the opening of 12 new clinical trials. This marks a decrease from the 18 trials that launched in May 2026, reflecting a slight shift in the pace of new research initiatives. Despite this, the new trials introduce important studies across various medical fields.

New trials this month are exploring a range of conditions, with the most frequent being heart failure (2 trials), followed by single trials for arthropathy of knee, bile duct cancer, brain cancer, critical illness, depression / major depressive disorder, gastroesophageal reflux, GERD, heartburn, and hiatal hernia. Behavioral trials lead the new study types with 5 new studies, followed by 4 device trials and 2 drug trials.

June brings several notable new trials to Cleveland, including studies from major sponsors and academic institutions:

• Stryker Orthopaedics is sponsoring NCT07647354, "Mako-MORE Registry." This prospective, post-market, multi-center, registry-based observational study aims for 950 participants to collect real-world clinical data on patients undergoing joint arthroplasty with Stryker implants, with or without the Mako Robotic-Arm Assisted System.
• The Cleveland Clinic is leading NCT07650669, "Wearable Technology in Heart Failure Patients." This registry, designed for 500 participants, will integrate continuous physiological data from consumer wearables with clinical data from patients' electronic health records.
• Case Western Reserve University is sponsoring NCT07630844, "REFRAME: an Emotion Regulation Intervention to Improve Psychological Outcomes in Surrogate Decision-Makers of the Critically Ill." This study, involving 387 participants, will assess a brief tablet-based program designed to help decision-makers manage emotions during critical medical decisions for loved ones in the intensive care unit.
• PROCEPT BioRobotics is initiating NCT07650448, "WATER IV PCa (AS Sub-study)." This multicenter, prospective, randomized clinical trial aims for 333 participants to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
• Also from The Cleveland Clinic, NCT07648290, "Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms," is an Early Phase 1 study for 260 participants. It investigates whether a standing, take-home prescription for empiric Macrobid is superior to standard triage for patients undergoing intradetrusor Botox® to manage urinary tract infections.
• The American Society of Pain and Neuroscience, Inc. is sponsoring a Phase 2 study, NCT07624279, "nVNS, CBD, and SoC for Persistent Post-Traumatic Headache." This trial, for 80 participants, aims to determine if cannabidiol (CBD) or vagus nerve stimulation reduce the frequency of persistent post-traumatic headache more than traditional oral headache medications.

Cleveland's Leading Research Institutions

Cleveland is home to a robust research ecosystem, with several institutions consistently leading in the volume of clinical trials. The Cleveland Clinic system, encompassing multiple entities, stands out as the primary hub for medical research in the city.

• Cleveland Clinic (344 trials)
• Cleveland Clinic Foundation (152 trials)
• University Hospitals Cleveland Medical Center (138 trials)
• Case Western Reserve University (78 trials)
• MetroHealth Medical Center (35 trials)
• Research Site (32 trials)
• The Cleveland Clinic Foundation (27 trials)
• Rainbow Babies and Childrens Hospital (25 trials)
• Louis Stokes VA Medical Center, Cleveland, OH (20 trials)
• Cleveland Clinic Main Campus (17 trials)
• Cleveland Clinic Cancer Center/Fairview Hospital (16 trials)
• University Hospitals (14 trials)

These institutions, particularly the various Cleveland Clinic entities and University Hospitals, offer a broad spectrum of research opportunities, from advanced surgical techniques to innovative drug therapies and behavioral interventions.

Who Can Participate? Diverse Opportunities

Participation in clinical trials is open to a diverse range of individuals. Of the 12 new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, 1 is female-only, and 2 are male-only. While none of the new trials specifically accept healthy volunteers, there are still 91 total clinical trials currently recruiting healthy participants across Cleveland, providing numerous avenues for those interested in supporting medical research without a specific condition.

Academic institutions continue to play a vital role in Cleveland's research ecosystem, with The Cleveland Clinic (4 trials) and Case Western Reserve University (1 trial) sponsoring a significant portion of new studies. Industry sponsors like PROCEPT BioRobotics (1 trial) and Stryker Orthopaedics (1 trial) are also driving important research efforts.

Expanding Your Search: Nearby Ohio Cities

While Cleveland offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Ohio. Cities with active trials include:

• Columbus (19 trials)
• Cincinnati (17 trials)
• Dayton (6 trials)
• South Euclid (2 trials)
• West Chester (2 trials)
• Milford (2 trials)
• North Royalton (1 trial)
• Wadsworth (1 trial)

As we move through June, Cleveland's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare, particularly for those who act quickly on trials nearing their enrollment deadlines.